Bivalirudin was initially approved by the United States Food and Drug Administration (FDA) on December 15, 2000.

Bivalirudin is primarily used as an anticoagulant in medical procedures. Its main uses include preventing blood clot formation during percutaneous coronary intervention (PCI) procedures, managing heparin-induced thrombocytopenia (HIT), serving as an alternative anticoagulant when heparin is contraindicated, and as part of anticoagulation strategies in certain cardiac surgeries. These applications help maintain blood flow, prevent clot formation, and manage thrombotic disorders in specific clinical contexts.

Bivalirudin is administered via the intravenous (IV) route. It is important to follow the dosing instructions provided on the product's packaging or as your healthcare provider recommends. 

Bivalirudin can have side effects. Common side effects include bleeding, which can range from minor oozing or bruising to more severe bleeding events. Pain at the injection site and headaches are also commonly reported. Additionally, there is a risk of allergic reactions, although they are rare, and they can manifest with symptoms like difficulty breathing, swelling of the face or throat, hives, or a rapid heartbeat. 

Bivalirudin significantly increases the risk of bleeding, which can be minor or major. Although rare, allergic reactions to bivalirudin can occur. It can cause a decrease in platelet count, which may lead to thrombocytopenia. It can potentially overdose, which can result in severe bleeding complications. 

Patients need close monitoring for signs of bleeding, such as easy bruising, uncontrolled bleeding, or blood in urine or stool after taking Bivalirudin. If any of the allergic reactions occur, immediate medical attention is necessary. Patients require regular monitoring of platelet levels, especially in patients at higher risk, and consider alternative anticoagulant strategies if significant thrombocytopenia develops.

Bivalirudin increases the risk of bleeding, so careful monitoring is crucial, especially in patients with kidney problems who may need dosage adjustments. While it has minimal impact on liver function, severe liver disease should still be monitored. Verify any allergies to heparin and take steps to prevent blood clot formation with appropriate dosing and monitoring. Be cautious of potential drug interactions, be prepared to manage allergic reactions, and use this medication during pregnancy or breastfeeding only when the benefits outweigh the risks. Limited data are available for pediatric use, and elderly patients may require extra monitoring. Additionally, be careful with alcohol consumption and avoid driving or operating heavy machinery if experiencing dizziness or other side effects.

1. KD Tripathi, Essentials of Medical Pharmacology, Drugs affecting coagulation, bleeding and thrombosis, 7th edition, 2013, 617, 620.
2. Medicines company, US Food and Drug Administration, [ Revised on March 2016], [ Accessed on April 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020873s036lbl.pdf
3. Accord Healthcare, Electronics Medicine compendium (EMC), [ Revised on May 2016], [ Accessed on 27th Sept 2023], https://www.medicines.org.uk/emc/files/pil.7229.pdf 

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.